Merit Medical Systems earnings date
Merit Medical Systems (MM3) Q3 2026 Earnings Report
DE:MM3 Q3 2026 EPS Results
- Actual EPS
- EUR 1.02
- Consensus EPS
- EUR 0.95
- Beat/Miss
- Beat by +EUR 0.07
- One Year Ago EPS
- EUR 0.84
DE:MM3 Q3 2026 Revenue Results
- Actual Revenue
- EUR 379.26M
- Expected Revenue
- EUR 373.51M
- Beat/Miss
- Beat by +EUR 5.75M
- YoY Revenue Growth
- +8.49%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- After Close
- Conference Call
- Thursday, October 29, 2026
Merit Medical Systems's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Merit reported better-than-expected revenue growth, expanding operating margin, higher EPS, strong free cash flow and raised 2026 guidance. Management also highlighted progress in strategic acquisitions, clinical evidence, product launches and long-term planning. The main challenges were lower gross margin, tariff exposure, elevated inventory, competitive pressure around WRAPSODY, difficult China market conditions and a slower-than-desired View Point integration, but these issues did not outweigh the quarter's operating performance and outlook.
For the 12 months ending December 31, 2026, Merit expects total GAAP net revenue growth in the range of 7.9% to 8.4% year-over-year and 7% to 7.5% year-over-year on a constant currency basis, excluding an expected 80 basis point tailwind to GAAP growth from changes in foreign currency exchange rates; sales of foundational products are expected to increase in the mid-single digits year-over-year and sales of therapeutic products to increase in the low double digits year-over-year, with organic constant currency growth in the range of 7.1% and 7.6%, acquisitions in the range of approximately $18 million to $19 million, DualCap sales of approximately $1.6 million in Q1 of 2026 versus $20.3 million in 2025, and U.S. WRAPSODY CIE revenue of approximately $7 million; non-GAAP diluted earnings per share is expected in the range of $4.33 to $4.37, reflecting expected growth in the range of 13% to 14% year-over-year, with full year 2026 non-GAAP operating margin in the range of 21.2% to 21.4%, up 94 to 116 basis points year-over-year; fourth-quarter total revenue is expected in the range of $418 million to $426 million, representing growth of 6% to 8% year-over-year on a GAAP basis and approximately 6% to 8% on a constant currency basis, organic constant currency growth is expected in the range of 7% to 8%, excluding acquisitions in the range of approximately $1.8 million to $2.9 million and revenue from a divestiture of $4.9 million in the prior year period, non-GAAP operating margins are expected in the range of approximately 21.2% to 22.1%, compared to 21% last year, and non-GAAP EPS in the range of $1.08 to $1.12, compared to $1.04 last year; tariff assumptions remain around $16 million, and for the 3-year period ending December 31, 2026, the company is targeting an organic constant currency revenue CAGR of 5% to 7%, non-GAAP operating margin in the range of 20% to 22% and cumulative free cash flow generation of more than $400 million.
- Q3 Revenue Exceeded ExpectationsThird-quarter total revenue was $416 million, up 8% year-over-year on both a GAAP and constant currency basis, exceeding the high end of the expectations provided on the Q2 earnings call.
- Strong Organic Growth Across Product CategoriesThird-quarter organic constant currency growth was 9%, also exceeding the high end of expectations and matching the 9% organic growth delivered in Q2. Foundational products grew 8% organically and therapeutic products grew 11% organically.
- Broad-Based Geographic and Product GrowthU.S. sales increased $25.9 million, or 11%, while international sales increased $5.1 million, or 3%. Total foundational product sales increased 6% and therapeutic product sales increased 13%. Organic foundational growth was driven primarily by vascular intervention, access and OEM, while organic therapeutic growth was driven primarily by oncology, endoscopy and OEM, with contributions from vascular intervention and cardiac therapies.
- Improved Operating Profitability and EPSNon-GAAP operating margin increased 160 basis points year-over-year to 21.3%, while total operating income increased $13 million, or 17%, to $88.5 million. Non-GAAP EPS increased 22% year-over-year, and net income increased to $67.4 million, or $1.12 per share, from $54.9 million, or $0.92 per share.
- Strong Cash Flow and Financial PositionMerit generated nearly $53 million of free cash flow in the third quarter. As of September 30, 2026, the company had $505.8 million of cash, cash equivalents and restricted cash, $747.5 million of total debt obligations, approximately $697 million of available borrowing capacity, and an adjusted net leverage ratio of 1.5x.
- Raised 2026 Revenue and EPS GuidanceThe company now expects 2026 total GAAP net revenue growth of 7.9% to 8.4% year-over-year, or 7% to 7.5% on a constant currency basis, including an expected 80 basis point foreign exchange tailwind. Organic constant currency growth is expected to be 7.1% to 7.6%, and non-GAAP diluted EPS guidance increased to $4.33 to $4.37 from $4.25 to $4.35, representing expected growth of 13% to 14%.
- Positive Fourth-Quarter OutlookFourth-quarter revenue is expected to be $418 million to $426 million, representing 6% to 8% year-over-year growth on both a GAAP and constant currency basis. Organic constant currency growth is expected to be 7% to 8%, with non-GAAP operating margin expected at approximately 21.2% to 22.1% versus 21% last year and non-GAAP EPS expected at $1.08 to $1.12 versus $1.04 last year.
- Progress Toward Three-Year Growth Initiative GoalsManagement said the company remains on track toward its three-year targets for the period ending December 31, 2026: organic constant currency revenue CAGR of 5% to 7%, non-GAAP operating margin of 20% to 22%, and cumulative free cash flow generation of more than $400 million. The CFO said the company expects to come in somewhere close to $600 million of free cash flow.
- View Point Medical and OneMark Integration ProgressThe integration of View Point Medical into the oncology platform continues to progress, with a strong pipeline of evaluations, particularly among academic institutions. OneMark enables clinicians to mark a breast cancer lesion at the time of biopsy, potentially reducing the need for a separate localization procedure before surgery, and complements the SCOUT MD product launched in late May.
- Clinical Evidence and Education ExpansionMerit completed the formal analysis of the AVF and AVG cohorts in the WRAPSODY Global Registry, with AVF data scheduled for presentation at the CiDA meeting. The company also doubled the number of Think Education courses hosted in U.S. and international markets over the last two years.
- Positive cTIF Clinical DataInvestigators presented randomized clinical data showing that cTIF with the EsophyX device was noninferior to laparoscopic Nissen fundoplication in GERD-related quality-of-life improvement and objective normalization of acid exposure, while being associated with lower rates of new-onset postoperative dysphagia.
- Solo Pace Acquisition Expands Cardiac TherapiesOn October 13, 2026, Merit paid approximately $45 million to acquire the remaining equity of Solo Pace, after previously holding an 18% equity ownership interest and serving as exclusive distributor. The acquisition adds the SOLO PACE CONTROL and SOLO PACE FUSION systems for temporary pacing during TAVR and other transcatheter heart valve procedures. Management said the transaction is immaterial to 2026 and slightly accretive to non-GAAP net income and EPS in 2027.
- Strong OEM and Oncology PerformanceThe OEM business increased approximately 15% in the third quarter after being essentially flat in the first half, resulting in approximately 5% growth year-to-date. Oncology increased approximately 16% in the quarter, supported in part by pent-up demand for the SCOUT MD rollout.
- Operational Leadership and Planning InitiativesSheri Lewis joined Merit as Chief Operations Officer, bringing three decades of experience across global operations, manufacturing and supply chain. Her initial priorities include launching integrated business planning, improving working capital efficiency and driving operational excellence. Merit is also nearing completion of its 2027-2029 strategic plan and plans to host an investor event on February 11, 2027.
- Continued Investment in Strategic Markets and ProductsManagement said it is continuing to prioritize investments in product pipeline opportunities and potential acquisitions across high-growth procedures and clinical platforms where Merit believes it has the right to win. The company also remains focused on embolics, with growth in both spheres and microcatheters, and intends to continue using minority investments as a way to evaluate technologies before potential full acquisitions.
DE:MM3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | 1.01- | 0.95 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 0.951.02 | 0.84 | 21.74% (+0.18) | |
| Jul 30, 2026 | 2026 (Q2) | 0.871.08 | 0.92 | 17.82% (+0.16) | |
| Apr 30, 2026 | 2026 (Q1) | 0.760.86 | 0.78 | 9.30% (+0.07) | |
| Feb 24, 2026 | 2025 (Q4) | 0.870.95 | 0.85 | 11.83% (+0.10) | |
| Oct 30, 2025 | 2025 (Q3) | 0.750.84 | 0.78 | 6.98% (+0.05) | |
| Jul 30, 2025 | 2025 (Q2) | 0.770.92 | 0.84 | 9.78% (+0.08) | |
| Apr 24, 2025 | 2025 (Q1) | 0.680.78 | 0.7 | 11.69% (+0.08) | |
| Feb 25, 2025 | 2024 (Q4) | 0.750.85 | 0.74 | 14.81% (+0.11) | |
| Oct 30, 2024 | 2024 (Q3) | 0.730.78 | 0.68 | 14.67% (+0.10) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


